Zibo, ChinaMay 9, 2026 /PRNewswire/ — The restructuring of the industry cycle presents a critical window for leading enterprises to establish long-term competitive advantages.
Over the past few years, the global disposable glove industry has faced multiple challenges, including supply-demand adjustments, capacity consolidation, and changes in the trade environment, with the industrial structure accelerating its shift towards high-quality leading enterprises. Against this backdrop, Intco Medical Technology Co., Ltd. (hereinafter referred to as “Intco Medical”) has maintained stable operations by leveraging its scale barriers, operational efficiency, and global layout, emerging as one of the few resilient companies amid cyclical fluctuations.
On April 24, Intco Medical released its 2025 annual report, showing that the company achieved operating revenue of 99.26 billion yuan in 2025, a year-on-year increase of 4.23%, hitting a new four-year high. Net cash flow from operating activities reached 1.885 billion yuan, a substantial year-on-year increase of 74.69%. Total assets at the end of the year exceeded 40 billion yuan, up 15.77% from the end of the previous year.
The first-quarter report for 2026, disclosed on the same day, showed that the company achieved operating revenue of 2.887 billion yuan in the first quarter, a year-on-year increase of 15.76%, with development momentum continuing to release. A research report from Orient Securities pointed out that against the backdrop of supply and demand in the global disposable glove industry trending towards rational balance and competition returning to cost and efficiency, Intco Medical, with its advantages in scale, cost, and globalization, is poised to increase its market share.
Having undergone deep industry reshuffling and cyclical iterations, this stable and improving operational performance, which enhances quality and efficiency, not only confirms Intco Medical’s solid industrial foundation and operational resilience but also reflects the core confidence and development logic of this global medical protective equipment leader in navigating industry fluctuations, anchoring long-term development, and driving high-quality growth through strategic layout.
Intco Medical Marketing Headquarters
Strengthening the Industrial Foundation: Building Core Competitive Advantages through Scale and Technology
In a period of deep market adjustment, cost control, economies of scale, and supply chain stability are the core foundations for companies to navigate fluctuations. Intco Medical adheres to a development path of scale, intelligence, and intensification, continuously consolidating its industrial base and constructing hard-to-replicate competitive barriers, thereby writing the first resilience code for navigating the cycle.
As of the end of 2025, the company’s annualized production capacity for disposable non-natural latex gloves exceeded 103 billion pieces, including 70 billion nitrile gloves and 33 billion PVC gloves, making its production scale the largest globally in the industry, providing solid support for stable global supply. Leveraging its massive capacity, the company has achieved significant economies of scale: on one hand, it continuously dilutes fixed costs such as plant, equipment, and management, opening up profit margins; on the other hand, it significantly enhances bargaining power in raw material procurement, taking an active position in industry price negotiations, with cost advantages continuously consolidated.
The disposable glove industry is a typical heavy asset, high-tech, long-cycle track, with extremely high barriers for new entrants. According to company disclosures, the investment for building a domestic dual-mold nitrile glove production line exceeds 25 million yuan, and the total investment for a full-scale glove factory exceeds 1 billion yuan, with a construction-to-production cycle of 12 to 18 months. Against the backdrop of continuous supply consolidation and strengthening head effects, Intco Medical, with its first-mover scale advantages and sustained investment, continues to widen the gap with the second-tier players, solidifying its leading position.
Technological upgrading is a core driver for Intco Medical to navigate the cycle. In 2025, the company built a fourth-generation dual-mold fully automatic nitrile glove production line with independent intellectual property rights, supported by a combined heat and power project, significantly improving production efficiency while reducing energy consumption. The company’s production yield rate has consistently remained above 99%, achieving fully automatic temperature control through a precision DCS control system, continuously improving product quality consistency and stability.
To address the risk of raw material price fluctuations, the company actively promotes vertical integration of the supply chain, holding controlling stakes in two and participating in two upstream nitrile latex production enterprises, achieving independent control and stable supply of core raw materials. In early 2026, due to changes in the international situation, glove raw material prices surged, and supply became unstable. Some companies in the industry reduced production or even shut down due to rising raw material costs and supply shortages. Intco Medical, with its stable supply chain, ensured full production and full sales, seizing market share counter-cyclically. This is a direct reflection of its risk hedging capability and an important foundation for building long-term development barriers and smoothly navigating the industrial cycle.
Optimizing Global Layout: Strengthening Development Resilience through Diversified Business and Stable Cash Flow
Operating cash flow is a core “touchstone” for assessing the profitability and risk resistance of cyclical companies and is also the second resilience code for Intco Medical to enhance its development momentum.
In 2025, Intco Medical’s net cash flow from operating activities increased by 74.69% year-on-year, far exceeding the revenue growth rate, highlighting its strong “cash generation” capability and efficient operational status.
Abundant cash flow builds a three-tier safety net: first, hedging against industry cyclical fluctuations to ensure continuous and stable production and operations; second, supporting the implementation of long-term strategies such as global capacity expansion and technological R&D; and third, continuously rewarding shareholders through cash dividends and share buybacks, conveying long-term development confidence. In 2025, the company proposed a distribution plan of 1.00 yuan cash dividend per 10 shares, simultaneously implementing share buybacks and cancellations to reward investors with real money.
Although affected by short-term non-operational factors such as increased financial expenses and exchange rate fluctuations, the company’s net profit attributable to the parent company experienced periodic volatility, its fundamental resilience remains unchanged. In response, the company has optimized its exchange rate hedging strategy, planning to convert some RMB loans into USD or HKD loans, leveraging the linked exchange rate mechanism and controllable financing costs to reduce external shocks and ensure stable operations.
While stabilizing the core business, the company’s profitability quality is also continuously improving. In 2025, Intco Medical’s overall gross margin reached 24.12%, an increase of 0.48 percentage points year-on-year. The company achieved profitability above the industry average through technological leadership and scale advantages. In the future, industry leaders will become more concentrated, and overall profitability will continue to improve.
Based on this development trend, facing the reshaping of the global market landscape, Intco Medical adheres to a deep global layout, constructing a “dual-engine” growth pattern driven by both domestic and international markets. In 2025, the company’s domestic revenue increased by 21.65% year-on-year, showing strong growth momentum in the local market. Overseas production bases in Vietnam and other locations have completed initial construction and commenced production smoothly, with multiple global marketing service centers established simultaneously, effectively hedging against the risk of fluctuations in a single market and continuously strengthening global resource allocation capabilities.
To smooth out industry cyclical fluctuations and expand long-term growth space, Intco Medical leverages its synergistic advantages in channels, brands, and technology to extend its business from single medical protection to comprehensive medical care, building a synergistic development system encompassing three major business segments: medical protection, rehabilitation medical equipment, and physiotherapy care.
In 2025, the company’s physiotherapy care products saw impressive growth, with a year-on-year increase of 38.08%, accelerating the formation of a “second growth curve.” The rehabilitation medical equipment segment launched intelligent products such as the E-LITE ultra-light carbon fiber wheelchair and the Dolly manual wheelchair. The physiotherapy care segment focuses on products like hot and cold therapy, leveraging channel reuse and technological synergy for rapid volume growth. The diversified layout effectively enhances customer stickiness and market space, injecting sustained momentum into the company’s high-quality and sustainable development.
Intco Medical Business Segments
Adhering to Innovation-Driven Development: Forging Core Competitiveness through Technology R&D and Green Development
Innovation is the third resilience code for Intco Medical’s long-term resilience. For a long time, Intco Medical has adhered to a “technology leadership” strategy. In 2025, the company’s R&D investment reached 404 million yuan, with an R&D expense ratio of 4.07%, significantly higher than the industry average. This sustained high-intensity R&D investment solidifies its technological barriers and seizes the high ground of industrial development.
The company focuses on breakthroughs in new materials, new products, and new processes, successfully launching innovative products such as Syntex™ synthetic latex gloves and Synmax Pro. These products overcome the limitations of natural latex, offering advantages such as low allergenicity and environmental friendliness, promoting the application of high-quality synthetic materials and creating high-performance, cost-effective products. At the same time, it is deploying differentiated products like hyaluronic acid gloves and pearlescent gloves, driving the company’s transition from “cost leadership” to “value leadership,” continuously enriching and optimizing its product matrix.
As of the end of 2025, the company and its subsidiaries held 298 patents, covering the entire chain from raw material formulas and automated production lines to intelligent manufacturing, forming a comprehensive technology reserve and innovation system. From smart equipment upgrades and raw material formula optimization to the launch and mass production of new products and the improvement of production process quality and efficiency, full-chain innovation implementation continuously enhances product premium capability and comprehensive competitiveness, accumulating endogenous momentum for the company’s long-term development.
With the continuous improvement of global green compliance systems, ESG and low-carbon development have become key variables for companies to participate in global competition. As the first company in the domestic industry to simultaneously obtain LCA certification and carbon footprint dual certification, in 2025, the company’s carbon emissions per glove dropped to 18.14 grams, a year-on-year decrease of 11.14%, achieving the phased goal of “reducing by 25% by 2030” five years ahead of schedule. Clean energy projects such as photovoltaic and wind power have been successively implemented and put into operation, continuously optimizing the energy structure. Additionally, Intco Medical has set a long-term goal of achieving carbon neutrality by 2050, steadily advancing its green and low-carbon transformation.
Green development capabilities are gradually transforming into hardcore market competitiveness. For example, Syntex™ synthetic latex gloves are not subject to EUDR restrictions, ensuring smooth access to global market channels. Furthermore, thanks to its excellent ESG practices, Intco Medical has received numerous domestic and international honors, including the Golden Dawn ESG Practice Award and Bloomberg Green ESG Leading Enterprise. Its sustainable development value has been widely recognized by the capital market and the global industrial chain. Green compliance has become a core passport for Intco Medical to deeply cultivate the global market and strengthen its long-term competitive barriers.
As the industry supply structure continues to optimize and the concentration effect on leading companies strengthens, Intco Medical has evolved from a single glove manufacturer into a comprehensive medical care service provider, completing a key leap from scale leadership to balancing quality and efficiency, and from domestic advantages to global competitiveness. Standing at a new starting point, Intco Medical is anchoring its five major operational focuses for 2026: accelerating the layout of overseas supply chains and production bases, deepening intelligent manufacturing and automation upgrades, increasing R&D for new products and improving the product matrix, expanding the global marketing network and optimizing market structure, and strengthening ESG governance to solidify sustainable development capabilities.
At this critical juncture where industrial cycle iterations and industry upgrades intersect, this healthcare enterprise, rooted in China and facing the world, is leveraging its hardcore strength to navigate cycles, opening up a new space for high-quality growth.